Key facts
- This page summarizes Christy J. Oliger's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 02 Sep 2026, 16:02.
Christy J. Oliger - 01 Sep 2026 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)
- Reporting relationship
- Director
- Issuer ticker
- ZBIO
- Reported as of
- 01 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Sep 2026, 16:02:08 UTC
- Prior SEC filing
- 29 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Chase Jayasekera, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Christy J. Oliger filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 02 Sep 2026.
Change
- Previous filing in this sequence was filed on 29 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001822092
Primary reporting owner
Oliger Christy J.
- Relationship
- Director
- Address
- C/O ZENAS BIOPHARMA, INC., 852 WINTER ST., SUITE 250, WALTHAM
- Signature
- By: /s/ Chase Jayasekera, Attorney-in-Fact
- Signature date
- 02 Sep 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZBIO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +37,000
- Change %
- Price
- $0.000000*
- Shares after
- 37,000
- Date
- 01 Sep 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,000
- Exercise price
- $31.98
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in equal annual installments over three years beginning on September 1, 2027, the first anniversary of the vesting commencement date, subject to continued service.